Biocryst Pharmaceuticals (BCRX) Receivables - Net (2023 - 2025)
Biocryst Pharmaceuticals' Receivables - Net history spans 9 years, with the latest figure at $4.0 million for Q4 2025.
- For Q4 2025, Receivables - Net fell 94.79% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, down 94.79%, while the annual FY2025 figure was $4.0 million, 94.79% down from the prior year.
- Receivables - Net reached $4.0 million in Q4 2025 per BCRX's latest filing, down from $91.3 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $93.4 million in Q1 2025 to a low of $381000.0 in Q2 2025.
- Average Receivables - Net over 3 years is $51.6 million, with a median of $55.3 million recorded in 2023.
- Peak YoY movement for Receivables - Net: surged 3100.72% in 2024, then crashed 99.43% in 2025.
- A 3-year view of Receivables - Net shows it stood at $54.1 million in 2023, then soared by 40.87% to $76.3 million in 2024, then plummeted by 94.79% to $4.0 million in 2025.
- Per Business Quant, the three most recent readings for BCRX's Receivables - Net are $4.0 million (Q4 2025), $91.3 million (Q3 2025), and $381000.0 (Q2 2025).